Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

65.51
+0.84501.31%
Volume:669.64K
Turnover:43.78M
Market Cap:12.66B
PE:172.86
High:66.30
Open:65.92
Low:64.33
Close:64.67
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:0.97
T/O Rate:0.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:2.00
PE(LYR):36.39

Loading ...

Biomarin Pharmaceutical Inc. : H.c. Wainwright Raises Target Price to $60 from $59

THOMSON REUTERS
·
Yesterday

U.s. Stocks on the Move-Pinterest, Intel, Slb

Reuters
·
Yesterday

Movement Alert|Biomarin Pharmaceutical Rises 5.08% in Pre-Market Trading, Reaches Global Patent Settlement With Ascendis Pharma Securing Up to 20% Royalty on Yuviwel Sales

Market Focus
·
Yesterday

Ascendis Enters Global Settlement, License Deal with BioMarin for Yuviwel Royalties

Reuters
·
Yesterday

Intel, ServiceNow, Chevron, Strategy, and More Stocks That Explain Today's Market

Dow Jones
·
Yesterday

BioMarin to receive 20% royalty on net sales of Yuviwel from Ascendis Pharma

TIPRANKS
·
Yesterday

Biomarin Pharmaceutical Shares up 5.6% Premarket After Co Announces Global Settlement with Ascendis Pharma

THOMSON REUTERS
·
Yesterday

BioMarin Settles Patent Lawsuits With Ascendis Pharma Over Yuviwel

MT Newswires Live
·
Yesterday

Biomarin Pharmaceutical - Settlement Includes License for Biomarin Patents Relating to Yuviwel for All Indications

THOMSON REUTERS
·
Yesterday

Biomarin Pharmaceutical - Ascendis to Pay Biomarin 20% Royalty on Yuviwel U.S. Sales, 18% in EU, Brazil, South Korea Until May 2030

THOMSON REUTERS
·
Yesterday

Biomarin Pharmaceutical - to Dismiss Itc Investigation; All Ip Claims Resolved Including Litigation in Multiple Countries

THOMSON REUTERS
·
Yesterday

BioMarin (BMRN) Stock Looks To Trade At A Discount To Fair Value

Simply Wall St.
·
Yesterday

U.S. Stocks on the MOVE-BioMarin Pharmaceutical, Home Depot, Klarna Group

Reuters
·
Aug 18

BioMarin Pharmaceutical's Alesta Deal Strengthens Long-Term Growth Outlook, Wedbush Says

MT Newswires Live
·
Aug 18

Biomarin Pharmaceutical Inc. : H.c. Wainwright Cuts Target Price to $59 from $60

THOMSON REUTERS
·
Aug 18

BioMarin Adds Potential Bone-Disease Treatment to Portfolio

Dow Jones
·
Aug 18

BioMarin Agrees to Buy Alesta Therapeutics for USD 275 Million Upfront

Reuters
·
Aug 18

Biomarin to Acquire Alesta Therapeutics to Gain Ale1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to Biomarin's Pipeline

THOMSON REUTERS
·
Aug 18

Biomarin Pharmaceutical - Deal Expected to be Modestly Dilutive to 2026 Financial Results

THOMSON REUTERS
·
Aug 18

Biomarin Pharmaceutical - Alesta Shareholders Eligible for up to $215 Mln in Milestone Payments

THOMSON REUTERS
·
Aug 18